Income Taxes (Details 3) - USD ($) |
Dec. 31, 2018 |
Dec. 31, 2017 |
|---|---|---|
| Net Deferred Tax Liability | ||
| Net Operating Loss Carryforwards | $ 13,601,705 | $ 12,624,253 |
| Research and Development Credit Carryforwards | 2,124,949 | 2,002,640 |
| Capitalized Research and Development | 5,861,675 | 5,172,541 |
| Nonqualified Stock Option | 639,729 | 552,096 |
| Depreciation and Amortization | (3,217) | (82) |
| Cash Versus Accrual Adjustments | 2,069,985 | 4,459,785 |
| Total Deferred Tax Assets | 24,294,826 | 24,811,233 |
| Valuation Allowance | (23,659,844) | (24,075,539) |
| Net Deferred Tax Asset | 634,982 | 735,694 |
| In-Process Research and Development | (904,950) | (919,617) |
| Net Deferred Tax Liability | $ (269,968) | $ (183,923) |
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset (liabilities) attributable to deductible temporary differences from property, plant, and equipment. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of deferred tax liability attributable to taxable temporary differences from research and development costs. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|